Physician Views: Can digital medicines become the norm?

The FDA recently approved Otsuka Pharmaceutical's Abilify (aripiprazole) MyCite as the first drug authorised in the US with a digital ingestion tracking system.

A sensor embedded in the tablet sends a message to a wearable patch, which transmits the information to a mobile application, allowing patients to track ingestion on their smart phone. In addition, patients can also permit their caregivers and physician to access the information through a web-based portal. Abilify MyCite is due to launch in early 2018 and pricing is yet to be disclosed.

To gauge reaction to the approval, we are snap-polling US and EU5-based psychiatrists and primary care practitioners with the following questions...

Would you recommend this to patients currently treated with Abilify/you are set to treat with Abilify?

Yes

No

Current FDA labelling for Abilify MyCite indicates that the digital sensor has only been shown to track doses and "ability of the product to improve patient compliance with their treatment regimen has not been shown."

Will this significantly limit utilisation (at least until any compliance/adherence data is subsequently published)?

Yes

No

To what extent do you think specific symptoms in patients typically treated with Abilify (i.e. paranoia) will adversely impact real-world use of Abilify MyCite?

None

Marginal impact

Moderate impact

Significant impact

Very significant impact

In certain indications, do you think drugs that incorporate digital ingestion tracking systems will be practice changing?

Yes

No

If priced suitably and supported by positive patient adherence data, will Abilify MyCite be practice changing in the indications Abilify is prescribed for?

Yes

No

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by Medefield MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

To read more Physician Views articles, click here.